Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

Table of Contents

Caduff,McHugh,Murer,Rämer,Raykova,Landtwing,Rieble,Keller,Prummer,Hoffmann,Lam,Chiang,Raulf,Azzi,Berger,Rubic-Schneider,Traggiai,Lünemann,Kammüller,and Münz: Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

The following information is missing from the Funding statement: AKSC was supported by a HMRF grant (18170462).

Reference

NCaduff, DMcHugh, AMurer, PRämer, ARaykova, VLandtwing, et al (2020) Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog 16(4): e1008477 10.1371/journal.ppat.1008477